Osiris Therapeutics

Osiris Therapeutics, Inc. is a stem cell company, which focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets. The company operates its business through two segments: Therapeutics and Biosurgery segment. The Therapeutics segment focuses on developing biologic stem cell drug candidates from readily available and non-controversial sources.

AngioDynamics

Ensign Group

Genomic Health

Ionis Pharma

Masimo

National Research Corp

These healthcare stocks will help you not only profit from the growing demand, but also the growing tech in the healthcare sector.

7 A-Rated Healthcare Stocks for Industry Expansion

While Osiris Therapeutics has appreciated 40% this year to $19, it is still undervalued.

Osiris Therapeutics Is Undervalued In Buyout

Smith & Nephew

On March 12, 2019, Osiris Therapeutics disclosed that Smith & Nephew agreed to acquire the company for $660 million.

News for Osiris Therapeutics Stock (OSIR)